Catherine Wood's ARKG Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 5,029 shares of ARK Genomic Revolution ETF (ARKG) worth $145,683, representing 0.00% of the portfolio. First purchased in 2020-Q4, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in ARKG, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2021, adding 37,478 shares. Largest reduction occurred in Q1 2022, reducing 46,541 shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's ARK Genomic Revolution ETF (ARKG) Holding Value Over Time
Track share changes against reported price movement
Quarterly ARK Genomic Revolution ETF (ARKG) Trades by Catherine Wood
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -2,022 | Reduce 28.68% | 5,029 | $28.97 |
| Q3 2025 | +2,730 | Add 63.18% | 7,051 | $27.77 |
| Q2 2025 | +429 | Add 11.02% | 4,321 | $24.35 |
| Q1 2025 | -2,097 | Reduce 35.01% | 3,892 | $20.76 |
| Q4 2024 | +2,521 | Add 72.69% | 5,989 | $23.55 |
| Q3 2024 | -3,872 | Reduce 52.75% | 3,468 | $25.60 |
| Q2 2024 | -777 | Reduce 9.57% | 7,340 | $23.48 |
| Q1 2024 | -1,062 | Reduce 11.57% | 8,117 | $28.76 |
| Q4 2023 | +5,155 | Add 128.11% | 9,179 | $32.81 |
| Q3 2023 | +829 | Add 25.95% | 4,024 | $27.86 |
| Q2 2023 | -2,837 | Reduce 47.03% | 3,195 | $34.09 |
| Q1 2023 | -10,102 | Reduce 62.61% | 6,032 | $30.07 |
| Q4 2022 | +14,553 | Add 920.49% | 16,134 | $28.23 |
| Q3 2022 | -9,126 | Reduce 85.23% | 1,581 | $32.89 |
| Q2 2022 | +3,858 | Add 56.33% | 10,707 | $32.22 |
| Q1 2022 | -46,541 | Reduce 87.17% | 6,849 | $45.99 |
| Q4 2021 | +37,478 | Add 235.53% | 53,390 | $61.25 |
| Q3 2021 | +7,521 | Add 89.63% | 15,912 | $74.72 |
| Q2 2021 | -2,344 | Reduce 21.84% | 8,391 | $92.48 |
| Q1 2021 | +9,065 | Add 542.81% | 10,735 | $88.78 |
| Q4 2020 | +1,670 | New Buy | 1,670 | $93.41 |
Catherine Wood's ARK Genomic Revolution ETF Investment FAQs
Catherine Wood first purchased ARK Genomic Revolution ETF (ARKG) in Q4 2020, acquiring 1,670 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held ARK Genomic Revolution ETF (ARKG) for 21 quarters since Q4 2020.
Catherine Wood's largest addition to ARK Genomic Revolution ETF (ARKG) was in Q4 2021, adding 53,390 shares worth $3.27 M.
According to the latest 13F filing for Q4 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 5,029 shares of ARK Genomic Revolution ETF (ARKG), valued at approximately $145,683.
As of the Q4 2025 filing, ARK Genomic Revolution ETF (ARKG) represents approximately 0.00% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.
Catherine Wood's peak holding in ARK Genomic Revolution ETF (ARKG) was 53,390 shares, as reported at the end of Q4 2021.